Overview

This trial is active, not recruiting.

Condition multiple myeloma and plasma cell neoplasm
Treatments cyclophosphamide, dexamethasone, idarubicin, lomustine, melphalan, prednisolone
Phase phase 3
Sponsor Riverside Haematology Group
Start date March 1998
Trial size 660 participants
Trial identifier NCT00003603, CDR0000066676, EU-98030, RHG-MM97

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Steroids, such as dexamethasone or prednisolone, may help relieve some of the side effects of chemotherapy. It is not yet known which regimen of chemotherapy plus steroid therapy is more effective in treating patients with multiple myeloma.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of chemotherapy plus steroid therapy in treating patients with multiple myeloma that has recurred for the first time.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Primary purpose treatment

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Diagnosis of multiple myeloma based on at least two of the following: - Paraprotein in serum and/or urine - Greater than 10% plasma cells in bone marrow - Lytic bone lesions - Measurable serum and/or urine paraprotein - Progression from first or second stable plateau phase - No non-secretory myeloma or plasma cell leukemia (greater than 2,000/mm^3 circulating plasma cells) - No primary refractory disease or second or later relapse PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - 0-3 Life expectancy: - Not specified Hematopoietic: - Neutrophil count at least 1,000/mm^3 - Platelet count at least 75,000/mm^3 Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - ALT/AST no greater than 2.5 times ULN Renal: - Creatinine less than 3.4 mg/dL Cardiovascular: - No clinically significant cardiac insufficiency - No uncontrolled hypertension Other: - No uncontrolled diabetes mellitus - No recent history of peptic ulceration - HIV-1 and HIV-2 negative - Fertile patients must use effective contraception during and for 6 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior allogeneic peripheral blood stem cell or bone marrow transplantation - No planned future autologous transplantation unless sufficient stored stem cells available - Prior interferon allowed if administered as maintenance of stable plateau phase - No concurrent epoetin alfa Chemotherapy: - At least 3 months since prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - Concurrent radiotherapy for pain or to treat localized tumors allowed Surgery: - Not specified Other: - No prior participation in any clinical trial with an unlicensed product

Additional Information

Official title A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma
Description OBJECTIVES: - Compare the response rate, response duration, and survival of patients with relapsed multiple myeloma after treatment with lomustine, idarubicin, and dexamethasone vs melphalan and prednisolone. OUTLINE: This is a randomized study. Patients are stratified according to prior autologous transplant (yes vs no). Patients are randomized to one of two treatment arms. - Arm I: Patients receive oral lomustine on day 1, oral idarubicin once daily on days 1-3, and oral dexamethasone twice a day on days 1-4. Treatment is repeated every 28 days for 6-9 courses in the absence of unacceptable toxicity or disease progression. - Arm II: Patients receive oral melphalan once daily on days 1-4 and oral prednisolone twice a day on days 1-4. Treatment is repeated every 28 days for 6-9 courses in the absence of unacceptable toxicity or disease progression. Some patients may receive oral cyclophosphamide every 7 days and oral prednisolone on alternate days for 6 weeks concurrently with chemotherapy in either treatment arm. Quality of life is assessed at baseline, at 3, 6, 9, and 12 months, and then every 6 months thereafter. Patients are followed until death. PROJECTED ACCRUAL: A total of 660 patients will be accrued for this study within 5 years.
Trial information was received from ClinicalTrials.gov and was last updated in September 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).